Merry Christmas and Happy New Year from Direct Peptides
We’ll be CLOSED on 25th, 26th December, and 1st January. Half-day openings on 27th and 31st December. Back to normal hours on 2nd January. Happy Holidays!

Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
Highest Quality | For Research Use Only

GDF-8 Myostatin

Buy GDF-8 Myostatin Peptide New Zealand

Growth Differentiation Factor 8 (GDF-8), commonly known as Myostatin, is a crucial peptide in the Transforming Growth Factor-beta (TGF-β) superfamily. New Zealand Research has shown it plays a pivotal role in regulating skeletal muscle mass, primarily acting as a negative regulator of muscle growth by inhibiting myogenesis, the formation process of muscular tissue.

New Zealand Research suggests the GDF-8 peptide’s function is particularly interesting when interacting with its endogenous inhibitor, Follistatin, which binds to GDF-8 and neutralizes its activity. This interaction has significant implications for potential therapeutic applications of GDF-8 peptides.

Showing all 3 results

Potential Benefits of GDF-8 Myostatin Peptide

  • Muscle Mass Enhancement: Myostatin (GDF-8) is a negative regulator of skeletal muscle growth and development. Studies have shown inhibition or loss of myostatin leads to an increase in skeletal muscle mass, providing therapeutic benefits for musculoskeletal disease [1] and [2].
  • Strength Improvement: Studies have demonstrated that inhibiting myostatin in adult mice improves their strength, suggesting potential benefits for humans [3].
  • Promotion of Myogenesis: In myostatin knockout mice, an increase in myogenesis – the formation of muscular tissue – was observed. Science indicates this could be beneficial for both human obesity research and treatments for muscle diseases [4].
  • Potential Metabolic Dysfunction Treatment: Research suggests targeting the signaling pathway of myostatin represents a potentially novel approach for addressing muscle loss and metabolic dysfunction, offering a promising avenue for treatment.[1].
  • Decrease in Adipogenesis: A decrease in adipogenesis, the process of cell differentiation by which pre-adipocytes become adipocytes (fat cells), was reported in a study on myostatin-deficient mice [4].
  • Chondrogenesis and Fracture Healing: Myostatin has been implicated in chondrogenesis, the process of cartilage formation, and fracture healing. Research suggests it could potentially be used to enhance these processes [2].

References

[1] https://pubmed.ncbi.nlm.nih.gov/18425412/

[2] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC3738019/

[3] https://pubmed.ncbi.nlm.nih.gov/24081623/

[4] https://www.sciencedirect.com/science/ article/abs/pii/S0006291X02965009

ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.

DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://new-zealand.direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.